Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02989155 · ClinicalTrials.gov registry record
Tranexamic Acid Use and Blood Loss in Total Hip Arthroplasty
A clinical trial, sponsored by Ohio State University.
- Completed
- Registry status
- 576
- Enrollment target
NCT02989155: Completed study, sponsored by Ohio State University.
NCT02989155 is a clinical trial that has completed, run by Ohio State University. The registered enrollment target is 576 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02989155 has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 576 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the need for a blood transfusion during surgery and to evaluate the levels of certain proteins in the blood when given tranexamic acid.
Primary Outcome
Whether intraoperative dose of 2gr tranexamic acid (TXA) in patients having primary or revision THA would decrease the perioperative and post-operative reduction in hemoglobin, hematocrit, and red blood cell transfusion rates compared with those of a similar group of patients who did not receive TXA (control group).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 576 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-12 |
What the finished NCT02989155 record still lists
NCT02989155 is an observational study that tracks outcomes without assigning an intervention. The registered 576 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02989155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02989155 about?
NCT02989155 is a clinical study titled "Tranexamic Acid Use and Blood Loss in Total Hip Arthroplasty". The purpose of this study is to determine the need for a blood transfusion during surgery and to evaluate the levels of certain proteins in the blood when given tranexamic acid.
What is the current status of trial NCT02989155?
This trial is currently completed. The enrollment target is 576 participants. The study started on 2016-01. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT02989155?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04931810 · 576 participants · NA
Urban and Reservation Implementation of All Nations Breath of Life
- NCT05179369 · 576 participants · NA
Well-Mama Community Doula Navigator Study
- NCT06398509 · 576 participants · NA
A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia